Trial Profile
A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2007
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Irinotecan (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 16 Aug 2005 New trial record.